O Ð.Â. åîïìïëïãåßôáé...

Boy Ôïí ðåñáóìÝíï Éïýíéï ëßãï ðñéí êëåßóù ôá 33, ðÞãá üðùò êÜèå ÷ñüíï íá êáíù ðñïëçðôéêÜ ôï HIV test óå ìéá éäéùôéêÞ êëéíéêÞ.

Ôçí åðüìåíç ìåñá, ôçí ÔåôÜñôç ìå ðÞñáí ôçëÝöùíï íá ðÜù íá îáíáäùóù áßìá, ãéáôé êÜôé ëÝåé äåí Þôáí óùóôü ìå ôï ìç÷Üíçìá ôïõò êáé ôï áðïôÝëåóìá äåí Ýâãáéíå êáé Ýðñåðå íá ôï îáíáêÜíïõí.
ÐÝìðôç ðñùß ëïéðüí îáíáðÞãá óôçí êëéíéêÞ.
ÅðôÜ åñãÜóéìåò çìÝñåò ëÝåé êáé ìåôÜ èá ðÜñù ôï áðïôÝëåóìá.
Ðåñíïýóáí ïé ìÝñåò ìÝóá óôï Üã÷ïò, ãéáôé åß÷á êáôáëÜâåé üôé êÜôé äåí ðÞãáéíå êáëá.
Äõï åâäïìÜäåò ìåôÜ Üñ÷éóá íá ðáßñíù êáèçìåñéíÜ ôçëÝöùíï óôçí êëéíéêÞ ãéá íá äù ôé ãßíåôáé êáé ìå ðÞãáéíáí áðï áíáâïëÞ óå áíáâïëÞ.

ÔåëéêÜ ìåôÜ áðï ìÞíá ãýñù óôá ôÝëç Éïõëßïõ ìå êáëÝóáíå íá ðÜñù ôï áðïôÝëåóìá.
Ìå êÜëåóå ç "ãéáôñüò" ôïõò óôï ãñáöåßï ôçò êáé áöïý ìïõ åßðå üôé ôï test åéíáé èåôéêü êáé üôé Ýðñåðå íá ðÜù óå Ýíá íïóïêïìåßï, ìïõ åßðå üôé ëõðÜôáé ðïëý óáí íá ìéëïýóå óå Ýíáí åôïéìïèÜíáôï.
Åãù ôçò åßðá, "ôé íá êÜíïõìå Ýôóé åéíáé ç æùÞ" êáé Ýöõãá.

Ôï áóôåßï åéíáé üôé ðáíôá ðñüóå÷á óôéò åðáöÝò ìïõ êáé áêüìá äåí å÷ù óêåöôåß êÜðïéï åðéêßíäõíï ðåñéóôáôéêü.
¼ðùò êáé íá ÷åé äåí Ý÷åé ðéá óçìáóßá.
Ãýñéóá ëïéðüí óðßôé êáé áöïý êÜèçóá óôï êñåâÜôé ìïõ ãéá äõï ïëüêëçñåò ìÝñåò áðïöÜóéóá íá ðÜù óå Ýíá äçìüóéï íïóïêïìåßï.
Åêåé ìïõ åßðáí üôé èá îáíáÝêáíáí ôçí åîÝôáóç ãéá íá õðÜñ÷åé ç äéÜãíùóç êáé áðï åêåé.
Ðåñßìåíá ëïéðüí Üëëç ìéá åâäïìÜäá íá ðÜñù ôçí áðÜíôçóç ðïõ Þîåñá.

ÐÜù ëïéðüí óôç ãéáôñü åêåé áöïý å÷ù äéáâÜóåé ôá ðáíôá ãéá ôïí hiv áðï ôï ºíôåñíåô, áöïý ùò ôïôå Þìïõí áíßäåïò.
Ç ãéáôñüò ìïõ ëÝåé üôé áöïý åéíáé ðñüóöáôç ç ëïßìùîç äåí èá ðñÝðåé íá áíçóõ÷þ êáé èá áñ÷éóù ôçí áíôéñåôñïúêÞ áãùãÞ óå ðÝíôå ìå äÝêá ÷ñüíéá.
Ìïõ Ýäùóå ôá ôçëÝöùíá áðï ôéò ÌÅË êÜðïéùí Üëëùí íïóïêïìåßùí ìÞðùò ìå âüëåõáí êáëýôåñá êáé üóç þñá Ýêáôóá åêåé áíôß íá ìïõ êáíåé ôçí ïðïßá åíçìÝñùóç åíïéùóá üôé ìå Ýóðñù÷íå íá ðÜù óå êÜðïéï Üëëï íïóïêïìåßï.
ÖõóéêÜ åðåéäÞ Þôáí ïé ôåëåõôáßåò ìÝñåò ôïõ Éïõëßïõ êáé ôïí Áýãïõóôï äå ãßíïíôáé åîåôÜóåéò, ìïõ Ýêëåéóå ñáíôåâïý ìÝóá ÓåðôÝìâñç ãéá ôï öïñôßï êáé ôá cd4.

¢ëëïò åíÜìéóõ ìÞíáò áíáìïíÞ.
Öüñôï åñãáóßáò óôç äïõëåéÜ, Üã÷ïò ãéá üëá áõôÜ, ÷ùñßò íá õðÜñ÷åé êÜðïéïò íá ìå âïçèÞóåé.
ÂñÞêá Ýíá ößëï áðï ôá ðáëéÜ ðïõ Þîåñá üôé äïýëåõå óå Ýíá äéáãíùóôéêü êÝíôñï ðïõ êé áõôüò åßíáé åðßóçò ïñïèåôéêüò, áëëÜ äåí ôï Þîåñá ùò ôïôå.
Ìïõ ðñüôåéíå íá ðÜù óå Ýíá Üëëï íïóïêïìåßï ðïõ óõíåñãÜæïíôáé ìå ôç äïõëåéÜ ôïõ.
Óêüðéìá äåí áíáöÝñù åäþ ôá ïíüìáôá ôùí íïóïêïìåßùí.
ÐÝñáóå ëïéðüí ï êáéñüò êáé ðÞãá íá êáíù ôéò åîåôÜóåéò.

¢ëëç ìéá åâäïìÜäá áíáìïíÞ.
Âãáßíïõí ôá áðïôåëÝóìáôá ìå 280 cd4 êáé 4800 öïñôßï. ÖõóéêÜ üôáí åßäá ôá cd4 Þôáí ðïõ Üñ÷éóá íá áã÷þíïìáé ðñáãìáôéêÜ.
Ðáßñíïõìå ôçëÝöùíï óôï Üëëï íïóïêïìåßï, ìáò äÝ÷ïíôáé êáé ìáò êëåßíïõí ñáíôåâïý.

¢ëëç ìéá åâäïìÜäá áíáìïíÞ.
ÖôÜíïõìå åêåé ìáæß. Äßíù óôïõò ãéáôñïýò ôéò åîåôÜóåéò êáé ìåôÜ áðï ëßãï âãáßíïõí Ýîù êáé ìéëÜíå ìå ôï ößëï ìïõ.
Åíþ ùò ôïôå åß÷áí äå÷ôåß íá ìå áíáëÜâïõí îáöíéêÜ Þôáí äýóêïëï, ãéáôé ëÝåé ÷ñåéáæüìïõí Üìåóá áãùãÞ.
Ìá áõôüò äåí åéíáé ï ñüëïò ôïõò;
Ìïõ åßðáí íá ðåñéìÝíù íá äïõí áí ìðïñïýí íá êÜíïõí êÜôé.

¢ëëåò ôñåéò ìÝñåò áíáìïíÞ.
Äåí ìå ðÞñáí ðïôå ôçëÝöùíï.
ÐÞñáí ôï ößëï ìïõ ãéá íá ôïõ äþóïõí ôçí áñíçôéêÞ áðÜíôçóç.
ÅðïìÝíùò êëåßíù ñáíôåâïý óå Ýíá Üëëï íïóïêïìåßï.

¢ëëåò äÝêá ìÝñåò áíáìïíÞ.
ÐÜù åêåé. Ï ãéáôñüò åõãåíÝóôáôïò, âëÝðåé ôéò åîåôÜóåéò ìïõ ëÝåé êáé áõôüò üôé ÷ñåéÜæïìáé Üìåóá áãùãÞ êáé ìïõ ðáßñíåé áßìá ãéá üëåò ôéò åîåôÜóåéò êáé ìïõ äßíåé ñáíôåâïý ãéá ôçí åðüìåíç åâäïìÜäá ðïõ èá ìïõ äþóåé åðéôÝëïõò ôçí áãùãÞ.

¢ëëç ìéá åâäïìÜäá áíáìïíÞ ëïéðüí.
Ðçãáßíù, ìïõ äåß÷íåé üëåò ôéò åíáëëáêôéêÝò áãùãÝò ðïõ ìðïñþ íá áêïëïõèÞóù áñ÷éêÜ ìÝ÷ñé íá Ý÷ïõìå ðëÞñç åéêüíá êáé äéáëÝãù ìéá áðï áõôÝò.
Ìïõ ëÝåé ÷ñåéÜæåôáé êÜðïéá äéáäéêáóßá åãêñßóåùí êáé ìïõ êëåßíåé ñáíôåâïý ôçí åðüìåíç ÔåôÜñôç.

¢ëëåò äÝêá ìÝñåò áíáìïíÞò.
Ôçí ÔåôÜñôç ðïõ ðÞãá êáé ðåñßìåíá äõï þñåò, ôåëéêÜ ìïõ åßðáí üôé Ýãéíå êÜðïéï ëÜèïò êáé üôé èá ôá åß÷áí ôçí ÐáñáóêåõÞ.
ÓÞìåñá åéíáé ÐáñáóêåõÞ êáé ôåëéêÜ ðÜëé äåí ôá åß÷áí.
Áðï ÄåõôÝñá êáé Ý÷åé ï èåüò.
Óôï ìåôáîý ôá cd4 Ýðåóáí óôá 210.
Óôï åíäéÜìåóï åìöáíßóôçêå êáé ðñüâëçìá ðåñéïäïíôéôéäáò êáé å÷ù ÷Üóåé Þäç 2 äüíôéá.

Ç õðïìïíÞ ìïõ ðëÝïí åîáíôëÞèçêå.
Ôüóç áðüãíùóç äåí Ýíéùóá ïýôå üôáí äéáãíþóôçêá ðïõ Þìïõí áíßäåïò êáé íüìéæá ðùò èá ðÝèáéíá.
Íïéþèù üôé ðíßãïìáé êáé èåëù ìéá áíÜóá êáé áõôïß ðïõ ìðïñïýí íá ìïõ ôç äþóïõí, ðáßæïõí ìáæß ìïõ.
Ï ößëïò ìïõ íïìßæåé üôé ÷ñåéÜæïìáé âïÞèåéá øõ÷ïëïãéêÞ ðëÝïí êé åãù îÝñù üôé óßãïõñá å÷ù óõìöéëéùèåß ìå ôçí éäÝá ôïõ hiv, áëëÜ üóï ìå áöÞíïõí Ýôóé åßìáé ëåò êáé æù óôï 1980.
Êáé ðåñéìÝíù ðïôå èá Ýñèïõí ôá óïâáñÜ ðñïâëÞìáôá.
Ãéá íá äïýìå ôé èá ãßíåé ôç ÄåõôÝñá.

Ð.Â.





... 'Aëëåò éóôïñßåò ...

+/-
ÌÜèå ôï status óïõ

Âñåò ôï ãéáôñü óïõ

ÐÜñå èåñáðåßá

¸ëåãîå ôï ééêü óïõ öïñôßï

Lancet

Ðñüóöáôåò äçìïóéåýóåéò óôï ðåñéïäéêü The Lancet HIV

Optimised second-line regimens in the public health approach

Globally, most people receive antiretroviral therapy (ART) in programmes that follow the WHO-recommended public health approach, using a small number of standard regimens and simplified monitoring.1 A single standard regimen—dolutegravir (an integrase strand transfer inhibitor [INSTI]) with tenofovir disoproxil fumarate and lamivudine (both nucleoside reverse transcriptase inhibitors, [NRTIs])—is currently taken by the large majority of people on ART in these programmes, including those on second-line therapy (following previous failure of a non-NRTI regimen).

Prioritising HIV drug resistance testing according to risk

Tenofovir–lamivudine–dolutegravir (TLD) is recommended as an initial treatment regimen and a preferred optimised regimen for people living with HIV without a history of previous viral non-suppression, referred to as TLD in first-line therapy (TLD-1). For people living with HIV with persistent viral non-suppression, TLD largely replaced protease inhibitor-based regimens following efavirenz-based initial regimens, referred to as TLD in second-line therapy (TLD-2), as it is at least as effective, better tolerated, and more affordable.

Ending paediatric AIDS: time to close implementation gaps

WHO's global health sector strategies on HIV, conceived to guide the health sector in implementing strategically focused responses to achieve the goals of ending AIDS by 2030, target a reduction in the number of children aged 0–14 years newly infected with HIV from 150 000 in 2022 to 20 000 in 2025 and 15 000 in 2030.1 To track progress toward these targets, accurate estimations of the number of annual infections in children in each country is crucial. However, in many low-income and middle-income countries, where the burden of paediatric HIV is the highest, children are not systematically tested for HIV in programmes for the prevention of vertical transmission (PVT).

About us

Óôï hivaids.gr, öéëïîåíïýìå áöéëïêåñäþò ôï "Ðñüãñáììá Óõíåñãáóßáò" ÌïíÜäùí Ëïéìþîåùí ãéá ôçí áíÜðôõîç äéáäéêôõáêÞò ôñÜðåæáò êëéíéêþí ðáñáìÝôñùí. Ôï Ðñüãñáììá äçìéïõñãÞèçêå áðü Ýíáí ãéáôñü åéäéêü óôçí HIV ëïßìùîç ìå ôç óõììåôï÷Þ ôùí ÌïíÜäùí: Ðåñéóóüôåñá

% Áíáðçñßá êáé HIV

ÍÝïò êáíïíéóìüò

Åíéáßïò Ðßíáêáò Ðñïóäéïñéóìïý Ðïóïóôïý Áíáðçñßáò

Çìåñïëüãéï

@ Äéáýãåéá

ÄéáýãåéáÄé@ýãåéá

äéáöÜíåéá óôï êñÜôïò

ÄéáäéêôõáêÝò áíáñôÞóåéò äéïéêçôéêþí áðïöÜóåùí ãéá ôï HIV/AIDS

Twitter

¸ñåõíá

Óáò Ý÷åé óðÜóåé ðïôÝ ôï ðñïöõëáêôéêü êáôÜ ôç äéÜñêåéá ìéáò åñùôéêÞò åðáöÞò;
Íáé
¼÷é
Äåí ÷ñçóéìïðïéþ

Åðéêïéíùíßá

Newsletter

Áíáêïéíþóåéò

×ñÞóéìåò ðëçñïöïñßåò